Catalog No.
Product Name
Application
Product Information
Citations
-
PPARα Agonist
CP-775146 is a selective agonist of peroxisome proliferator-activated receptor alpha (PPARα) with a binding affinity of Ki 24.5 nM. This compound exhibits significant hypolipidemic activity, effectively reducing lipid accumulation in liver tissues. CP-775146 is particularly useful in research focused on obesity-related liver damage, as it promotes fatty acid β-oxidation and supports metabolic health. -
PPAR Antagonist
Amezalpat is a selective antagonist of PPARα, exhibiting an IC50 value of 58 nM. This compound demonstrates notable antineoplastic activity, making it a valuable tool for research in cancer biology and therapeutic applications targeting metabolic regulation and lipid homeostasis. Its use in scientific studies may help elucidate the role of PPARα in tumor progression and treatment resistance. -
PPARδ/γ Agonist
PPARδ/γ agonist 1 sodium is a selective dual agonist for peroxisome proliferator-activated receptors delta and gamma. This compound exhibits significant biological activity, promoting the activation of PPAR signaling pathways. It is particularly useful in research exploring metabolic processes and neurodegenerative diseases such as Alzheimer’s disease. -
PPARγ Agonist
MRL-24 is a potent PPARγ agonist that plays a crucial role in regulating glucose and lipid metabolism. It has been demonstrated to enhance insulin sensitivity and may be utilized in research related to metabolic diseases, including obesity and type 2 diabetes. This compound is valuable for studies exploring the therapeutic potential of PPARγ activation in metabolic disorders. -
PPARα Agonist
LY518674 is a potent and selective agonist of peroxisome proliferator-activated receptor alpha (PPARα), exhibiting an EC50 of 42 nM for human PPARα. This compound is effective in reducing triglyceride levels and increasing high-density lipoprotein cholesterol (HDL-C). It is primarily applied in research related to lipid metabolism and the treatment of atherosclerosis. -
PPARα Agonist
CP-868388 free base is a selective and potent agonist of peroxisome proliferator-activated receptor alpha (PPARα) with a Ki value of 10.8 nM. This compound demonstrates minimal affinity for PPARβ and PPARγ, indicating its specificity. CP-868388 free base exhibits significant hypolipidemic and anti-inflammatory properties, making it a valuable tool for research into metabolic disorders and inflammation pathways. -
PPARα/γ Ligand
LT175 is a dual ligand targeting peroxisome proliferator-activated receptors alpha and gamma (PPARα/γ). As an orally active partial agonist, it exhibits effective receptor affinity with EC50 values of 0.22 μM for hPPARα, 0.26 μM for mPPARα, and 0.48 μM for hPPARγ. LT175 modulates coregulator recruitment, specifically cyclic-AMP response element-binding protein-binding protein and nuclear corepressor 1 (NCoR1), via interaction in the hydrophobic "diphenyl pocket" of PPARγ. This compound demonstrates significant insulin-sensitizing effects while reducing adipogenic activity, making it valuable for research in metabolic disorders. -
PPAR Agonist
AM3102 is a potent agonist of peroxisome proliferator-activated receptor alpha (PPAR-alpha). This endogenous high-affinity compound, an analog of oleoylethanolamide (OEA), is resistant to enzymatic hydrolysis, allowing for sustained activation of PPAR-alpha in vitro. Research demonstrates that AM3102 effectively reduces feeding behavior when administered both parenterally and orally, making it a valuable tool for studies on metabolism and appetite regulation. -
PPAR Agonist
PPAR Agonist 5 is a potent agonist of peroxisome proliferator-activated receptors (PPARs), specifically exhibiting EC50 values of 3.20 µM for PPARα, 1.51 µM for PPARβ/δ, and 1.92 µM for PPARγ. This compound demonstrates significant anti-inflammatory effects, making it valuable for research in metabolic disorders, inflammation, and various cardiovascular diseases. Its ability to modulate PPAR activity positions it as a useful tool in studies aimed at understanding PPAR-related signaling pathways. -
PPARγ Inverse Agonist
SR10221 is a noncovalent inverse agonist of peroxisome proliferator-activated receptor gamma (PPARγ). This compound exhibits significant biological activity by repressing downstream PPARγ target genes, which contributes to growth inhibition in bladder cancer cell lines. SR10221 is primarily utilized in research applications aimed at understanding PPARγ signaling pathways and developing potential therapeutic strategies for bladder cancer. -
PPAR α/γ agonist
Muraglitazar is a dual agonist of peroxisome proliferator-activated receptors alpha (PPARα) and gamma (PPARγ). It demonstrates potent agonistic activity with an EC50 of 320 nM for human PPARα and 110 nM for PPARγ, making it valuable in the study of type 2 diabetes and related dyslipidemia. Muraglitazar's mechanism aids in understanding the metabolic effects and therapeutic potential for managing insulin sensitivity and lipid profiles. -
PPARγ Agonist
BVT.13 is a selective agonist of peroxisome proliferator-activated receptor gamma (PPARγ) with high oral bioavailability. This compound demonstrates significant antidiabetic activity, as evidenced by its efficacy in ob/ob mice models. BVT.13 is a valuable tool for researching metabolic disorders and the mechanisms of insulin sensitivity. -
PPARγ Agonist
(±)4-HDHA (4-Hydroxy docosahexaenoic acid) primarily acts as a PPARγ agonist. It demonstrates significant antidiabetic and anti-inflammatory properties, making it useful in studies related to metabolic diseases and inflammation. This compound serves as a valuable reagent for researchers exploring the roles of PPARγ activation in various biological processes. -
PPARγ Antagonist
SR 11023 is a potent orally active antagonist of PPARγ, exhibiting an IC50 value of 109 nM. This compound is significant in the study of metabolic disorders, particularly in diabetes research, where PPARγ modulation can impact insulin sensitivity and adipocyte differentiation. Researchers can utilize SR 11023 to investigate the therapeutic potential of targeting PPARγ in various metabolic pathways. -
PPAR-γ Activator
SP4f is a potent PPAR-γ activator, exhibiting an EC50 of 826 nM in HK-2 cells. This compound has been shown to lower blood glucose levels and decrease lipid peroxidation, while also enhancing glutathione levels and catalase activity in Swiss albino mice. SP4f is valuable for research focused on metabolic regulation, diabetes, and oxidative stress. -
PPARγ Inverse Agonist
BAY-0069 is a selective inverse agonist of PPARγ, exhibiting potent inhibition with IC50 values of 6.3 nM for human PPARγ and 24 nM for mouse PPARγ. This compound serves as a valuable tool for investigating the roles of PPARγ in cancer research, providing insights into its regulatory mechanisms in tumorigenesis and potential therapeutic strategies. Its high selectivity enhances its utility in experimental settings. -
PPARγ Partial Agonist
GQ-16 is an orally active partial agonist of PPARγ, exhibiting an IC50 of 1.84 μM and a Ki of 160 nM against human PPARγ. This compound effectively inhibits Cdk5-mediated Ser-273 phosphorylation, enhancing insulin sensitivity and glucose tolerance in obese and diabetic mouse models. Additionally, GQ-16 demonstrates cytotoxic effects against various tumor cell lines, making it a valuable reagent for research on obesity, diabetes, and cancer. -
PPARα/γ agonist
Ragaglitazar is a dual agonist of PPARα and PPARγ, exhibiting strong lipid-lowering and insulin-sensitizing properties. This compound has been shown to enhance glycemic control and improve lipid profiles in animal models of type 2 diabetes, making it a valuable tool for research in metabolic disorders and potential therapeutic applications in diabetes management. -
PPARy Agonist
PPARγ agonist 14 is a potent PPARγ agonist with an EC50 of 2.4 μM, demonstrating significant anti-diabetic activity. This compound enhances intracellular glucose uptake, promotes insulin secretion, and effectively lowers blood glucose levels. Additionally, PPARγ agonist 14 is known to improve mitochondrial function, mitigate oxidative stress, and inhibit inflammatory factors, making it valuable for research into neurodegenerative and neuroinflammatory diseases, as well as other metabolic disorders. -
PPARα/PPARδ Agonist
PPARα/δ Agonist 1 is a potent dual agonist targeting PPARα and PPARδ, exhibiting an EC50 of 7.0 nM for PPARα and 8.4 nM for PPARδ, while demonstrating high selectivity over PPARγ with an EC50 of 1316.1 nM. This compound is valuable for research focused on metabolic disorders, particularly non-alcoholic steatohepatitis, as it may enhance lipid metabolism and anti-inflammatory responses. -
PPARγ Agonist
PPARγ Agonist 5 is a potent and selective agonist targeting peroxisome proliferator-activated receptor gamma (PPARγ). This compound exhibits key biological activity in modulating glucose and lipid metabolism, making it a valuable tool for investigating metabolic disorders, including obesity and type 2 diabetes. Additionally, its role in cancer research highlights its potential for understanding the mechanisms of tumorigenesis and cancer progression. -
PPARγ Agonist
Methyl oleanonate is a natural triterpene that acts as an agonist for peroxisome proliferator-activated receptor gamma (PPARγ). Isolated from Pistacia lentiscus var. Chia, this compound exhibits significant anti-cancer properties and is of interest in research focused on metabolic regulation and tumorigenesis. Its ability to modulate PPARγ makes it a valuable tool for investigating pathways related to metabolism and cancer therapeutics. -
PPARγ Inhibitor
PPARγ phosphorylation inhibitor 1 is a selective inhibitor targeting Peroxisome Proliferator-Activated Receptor gamma (PPARγ). It effectively inhibits CDK5-mediated phosphorylation of PPARγ at Ser273 with an IC50 of 160 nM, demonstrating a binding affinity with an IC50 of 24 nM. This compound exhibits minimal PPARγ agonistic activity in reporter gene assays, making it a valuable tool for studying the role of PPARγ phosphorylation in metabolic disorders and antidiabetic research applications. -
PPAR Agonist
Palmitoyllactic acid is a PPAR agonist that exhibits lipogenic activity. It has been shown to induce a brown fat-like phenotype in 3T3-L1 adipocytes by enhancing the expression of key genes associated with brown/beige adipocyte differentiation, including Prdm16 and Pgc1a. Additionally, palmitoyllactic acid significantly promotes adipogenesis in conjunction with dexamethasone. This compound is valuable for research into obesity and metabolic disorders. -
PPARα Agonist
PPARα Agonist 6 functions as an agonist of peroxisome proliferator-activated receptor alpha (PPARα). It plays a critical role in the regulation of lipid metabolism and can be utilized in research focused on dyslipidemia and related metabolic disorders. This compound supports studies aimed at understanding the molecular pathways involved in lipid homeostasis and the therapeutic potential of targeting PPARα. -
PPARγ Agonist
9-Octadecynoic acid is a selective agonist of peroxisome proliferator-activated receptor γ (PPARγ), known to modulate gene expression involved in lipid metabolism and insulin sensitivity. This compound demonstrates strong biological activity in cellular systems, making it a valuable tool for studying metabolic disorders and obesity-related research. Its role as a PPARγ activator enables investigations into the mechanisms of action related to glucose homeostasis and fatty acid storage. -
PPARγ agonist
Farglitazar is a potent PPARγ agonist that plays a crucial role in regulating glucose metabolism. This compound is particularly relevant in the study of type 2 diabetes, exhibiting significant glycemic control effects. Its ability to modulate insulin sensitivity makes it a valuable tool for research into diabetes management and related metabolic disorders. -
PPARG Inverse Agonist
BAY-5094 is an inverse agonist of the peroxisome proliferator-activated receptor gamma (PPARG). This compound exhibits oral bioactivity and has potential applications in the study of luminal bladder cancer. Its mode of action allows for investigation into the role of PPARG in tumorigenesis and cancer progression. -
PPAR-γ Ligand
Glycyrin is a potent ligand for the peroxisome proliferator-activated receptor gamma (PPAR-γ). This compound has demonstrated the ability to lower blood glucose levels in genetically diabetic mice, indicating its potential role in diabetes research. Additionally, glycyrin exhibits antibacterial properties, making it applicable in studies related to infectious diseases. -
PPARα/γ Agonist
Wistin is a selective agonist of peroxisome proliferator-activated receptors (PPARα and PPARγ), derived from the roots of Caragana sinica. It demonstrates significant biological activity in regulating lipid metabolism and glucose homeostasis. Wistin is commonly utilized in research focused on metabolic disorders, diabetes, and cardiovascular diseases, providing insights into the therapeutic potential of PPAR modulation. -
PPAR Ligand
9-HEPE is a PPAR ligand derived from the oxidation of Eicosapentaenoic acid, comprising a racemic mixture of 9(R)-HEPE and 9(S)-HEPE. It enhances fatty acid oxidation, promotes adipogenesis, and increases glucose uptake through the activation of peroxisome proliferator-activated receptors (PPARs) in vivo. This compound is instrumental for research applications focusing on metabolic regulation and disorders related to obesity and insulin sensitivity. -
PPARalpha/PPARgamma Activator
20-Carboxyarachidonic acid is an endogenous dual activator of PPARalpha and PPARgamma. As a stable metabolite of 20-HETE, it plays a significant role in regulating lipid metabolism and inflammation. This compound is utilized in research exploring metabolic disorders, cardiovascular diseases, and the modulation of inflammatory responses. -
PPARγ Agonist
10-Nitrolinoleic acid is a potent agonist of peroxisome proliferator-activated receptor γ (PPARγ). It demonstrates the ability to compete with [3H]Rosiglitazone for binding to PPARγ, achieving an IC50 value of 0.22 μM. This compound is valuable for research focused on metabolic regulation and the modulation of insulin sensitivity, making it relevant in studies of obesity and type 2 diabetes. -
PPAR-γ Activator
SP4e is a selective activator of peroxisome proliferator-activated receptor gamma (PPAR-γ), exhibiting an EC50 of 739 nM in HK-2 cells. This compound displays significant biological activity by lowering blood glucose levels and reducing lipid peroxidation, while simultaneously enhancing glutathione levels and catalase activity in Swiss albino mice. SP4e can be employed in research focused on metabolic disorders, oxidative stress, and related therapeutic pathways. -
ABCA1 Inducer/PPARs Agonist
E17241 is an inducer of ATP-binding cassette transporter A1 (ABCA1) that significantly enhances ABCA1 protein levels in RAW 264.7 macrophages. It also acts as an agonist for peroxisome proliferator-activated receptors (PPARs), contributing to metabolic regulation. Notably, E17241 has demonstrated the capability to reduce plasma glucose levels and body weight in KKAy diabetic mice subjected to a high-fat and high-glucose diet, making it a valuable reagent for research on lipid metabolism and diabetes management. -
PPAR-α/δ Inhibitor
Anti-NASH agent 1 is a potent PPAR-α/δ inhibitor that effectively targets nonalcoholic steatohepatitis (NASH). This compound has demonstrated significant efficacy in improving hyperlipidemia, liver fat degeneration, and liver inflammation in a methionine-choline deficiency (MCD) induced NASH mouse model. Additionally, Anti-NASH agent 1 exhibits low liver toxicity while providing protective effects on liver health, making it a valuable tool for research into metabolic disorders and liver diseases. -
PPARγ agonist
Amorfrutin B is a potent agonist of peroxisome proliferator-activated receptor gamma (PPARγ), with Ki values of 19 nM and an EC50 of 73 nM, indicating strong bioactivity. This compound exhibits hypoglycemic effects and provides neuroprotective benefits, making it valuable for research in metabolic disorders and neurobiology. Its oral activity further enhances its potential for in vivo studies focused on PPARγ modulation. -
PPARγ Inhibitor
Soyasaponin Aa is a PPARγ inhibitor that demonstrates significant anti-obesity effects in 3T3-L1 adipocytes by downregulating the activity of peroxisome proliferator-activated receptor γ. Its biological activity supports research into mechanisms of adipogenesis and metabolic regulation. Soyasaponin Aa is useful in studies aimed at understanding the therapeutic potential of targeting PPARγ in obesity-related conditions. -
PPAR Agonist
Naveglitazar is a non-thiazolidinedione peroxisome proliferator-activated receptor (PPAR) α-γ dual agonist, exhibiting a predominant effect on PPARγ. It has demonstrated significant glucose-lowering activity in various animal models, making it a valuable tool for research into insulin sensitivity and metabolic diseases. Its dual action on PPARα and PPARγ positions Naveglitazar as a potential candidate for investigating therapeutic approaches for type 2 diabetes and related metabolic disorders. -
PPAR Activator
13-Oxo-9E,11E-octadecadienoic acid acts as a potent PPARα activator and is derived from tomato juice. This compound has demonstrated the ability to reduce plasma and hepatic triglyceride levels in obese diabetic mouse models. Its applications in research include the study of metabolic disorders and potential therapeutic strategies for obesity-related conditions. -
PPARγ Agonist
PPARγ Agonist 11 is a selective agonist of the peroxisome proliferator-activated receptor gamma (PPARγ) with an EC50 of 0.1 μM. This compound is instrumental in the study of metabolic disorders, including obesity and type 2 diabetes, by activating PPARγ pathways involved in glucose and lipid metabolism. Its role in modulating insulin sensitivity makes it a valuable tool for research into therapeutic interventions for metabolic diseases. -
PPARδ Activator
E0924G is an orally active PPARδ activator with an EC50 of 2.82 μM. This compound effectively induces the upregulation of osteoprotegerin (OPG) with an EC50 of 0.29 μM, demonstrating significant inhibition of RANKL-induced osteoclast differentiation and F-actin ring formation in RAW264.7 macrophages. E0924G has potential applications in research focused on bone density regulation and the treatment of bone loss in models of ovariectomized and age-related osteoporosis. -
PPARγ Ligand
SKLB102 is a potent PPARγ ligand that demonstrates high affinity for the nuclear receptor. It effectively reduces fat deposition and offers protective effects against non-alcoholic fatty liver disease (NAFLD) by modulating adipocytokine expression and preventing insulin resistance. This compound is valuable for research focused on metabolic disorders and the regulation of lipid metabolism. -
PPAR-δ Agonist
Seladelpar (lysine) is a selective agonist of the PPAR-δ receptor, demonstrating high potency with an EC50 of 2 nM. It exhibits over 750-fold and 2500-fold selectivity towards PPAR-α and PPAR-γ, respectively. Seladelpar (lysine) is primarily utilized in research focused on primary biliary cholangitis and related metabolic disorders, providing valuable insights into lipid metabolism and liver function. -
PPARG Agonist
2-Ethylhexyl diphenyl phosphate is a PPARG agonist with an effective concentration (EC20) of 2.04 µM. It also demonstrates inhibitory activity on ERRγ transcriptional activity with an IC50 of 1.3 µM. This compound is known to upregulate 3β-HSD1, enhance human chorionic gonadotropin (hCG) production, and stimulate progesterone secretion. It serves as a valuable tool for investigating mechanisms of female reproduction and fetal development in biochemical research. -
PPARγ Activator
5-Aminosalicylic acid-13C6 hydrochloride is a labeled variant of 5-Aminosalicylic acid, functioning primarily as a PPARγ agonist. This compound exhibits significant biological activity by inhibiting p21-activated kinase 1 (PAK1) and the transcription factor NF-κB. It is commonly utilized in research concerning metabolic disorders, inflammation, and immune response pathways. -
PPAR
Naveglitazar racemate is a non-thiazolidinedione agonist targeting peroxisome proliferator-activated receptors (PPAR) α and γ, with a dominant effect on PPAR γ. This compound has demonstrated significant glucose-lowering activity in various animal models, making it a valuable tool for research in metabolic disorders. It is applicable in studies focused on diabetes and obesity, particularly in understanding the mechanisms of dual PPAR activation and its implications for therapeutic strategies. -
PPAR Agonist
PPAR Agonist 1 is a selective agonist of peroxisome proliferator-activated receptors (PPAR) α and γ. It demonstrates significant biological activity in the regulation of glucose and lipid metabolism, effectively lowering blood glucose and cholesterol levels while promoting weight reduction. This compound is suitable for research applications targeting metabolic disorders and investigating the effects of PPAR activation on energy homeostasis. -
PPARα Agonist
PPARα Agonist 2 is a potent and selective agonist specifically targeting the peroxisome proliferator-activated receptor alpha (PPARα) with an EC50 of 37 nM. It demonstrates more than 2,700-fold selectivity over other PPAR isoforms. This compound is valuable for research focused on retinal disorders and other related metabolic studies. -
Dual ACLY inhibitor/PPARα Agonist
BGT-002 is a potent dual inhibitor of ATP-citrate lyase (ACLY) and a peroxisome proliferator-activated receptor alpha (PPARα) agonist. This compound effectively reduces lipogenesis by inhibiting fatty acid synthesis and enhancing lipid efflux. BGT-002 has shown efficacy in improving metabolic dysfunction-related steatohepatitis and hyperlipidemia in vivo, making it a valuable reagent for research into hypercholesterolemia and related metabolic disorders.
